monobenzone, 103-16-2

Articles:

PubMed:	Different effects of five depigmentary compounds, rhododendrol, raspberry ketone, monobenzone, rucinol and AP736 on melanogenesis and viability of human epidermal melanocytes.
PubMed:	A mouse model of vitiligo induced by monobenzone.
PubMed:	Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
PubMed:	Successful treatment of extensive vitiligo with monobenzone.
PubMed:	Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
PubMed:	The therapeutic effects of EGCG on vitiligo.
PubMed:	Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
PubMed:	Pre-clinical evidences of Pyrostegia venusta in the treatment of vitiligo.
PubMed:	A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity.
PubMed:	Corneal and conjunctival effects of monobenzone in patients with vitiligo.
PubMed:	Monobenzone, Superfade, vitiligo and confetti-like depigmentation.
PubMed:	Dermatitis produced by applications of monobenzone in patients with active vitiligo.
PubMed:	Diffuse leukoderma following use of monobenzone.
PubMed:	MONOBENZONE.
PubMed:	Evaluation of monobenzone.
PubMed:	Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.
PubMed:	Breaking immunological tolerance to melanocyte differentiation antigens by hypopigmenting agents: a new means for melanoma immunotherapy?
PubMed:	Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
PubMed:	Accelerating bleaching in vitiligo: balancing benefits versus risks.
PubMed:	Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.
PubMed:	Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8.
PubMed:	Depigmentation therapies for normal skin in vitiligo universalis.
PubMed:	The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology.
PubMed:	How we treat vitiligo.
PubMed:	Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
PubMed:	New and experimental treatments of vitiligo and other hypomelanoses.
PubMed:	Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.
PubMed:	Footwear depigmentation.
PubMed:	Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone.
PubMed:	Achromic patch test from hydroquinone monobenzyl ether.
PubMed:	The Seiji memorial lecture. Pigment stories: from vitiligo to melanomas and points in between.
PubMed:	Contact depigmentation of the breast.
PubMed:	Should vitiligo be treated?
PubMed:	[Leukomelanodermia areata (dyschromia "en confetti") caused by the application of monobenzylether of hydroquinone (author's transl)].
PubMed:	[Irreversible toxic depigmentation. Observations following use of hydroquinonemonobenzylether-containing skin bleaching preparations].
PubMed:	Contact hypersensitivity to monobenzyl ether of hydroquinone used to treat vitiligo.
PubMed:	Dyschromatosis.
PubMed:	A case report of extensive vitiligo.
PubMed:	Treatment of nonhairy melanocytic macules by dermabrasion and topical application of 5% hydroquinone monobenzyl ether cream.
PubMed:	Hearing aid depigmentation.
PubMed:	Influence of depigmenting chemical agents on hair and skin color in yellow (pheomelanic) and black (eumelanic) mice.
PubMed:	[Confetti-like dyschromia caused by a bleaching cream containing hydroquinone in racially pigmented patients].
PubMed:	Modulation of the population density of identifiable epidermal Langerhans cells associated with enhancement or suppression of cutaneous immune reactivity.
PubMed:	[Treatment of vitiligo].
PubMed:	[Therapy of melanin-induced pigment anomalies].
PubMed:	Sensitization to hydroquinone and the monobenzyl ether of hydroquinone.
PubMed:	[Acquired leukomelanoderma caused by topical depigmenting agents].
PubMed:	Screening of depigmenting compounds for the development of an alternate method of branding beef cattle.
PubMed:	[Eye diseases attributable to dermatologic therapy].
PubMed:	Vitiligo: a manifestation of apoptosis?
PubMed:	Vitiligo.
PubMed:	Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation.